[go: up one dir, main page]

ZA200806070B - Combination of ache inhibitor and 5-HT6 antagonist for the treatment of cognitive dysfunction - Google Patents

Combination of ache inhibitor and 5-HT6 antagonist for the treatment of cognitive dysfunction

Info

Publication number
ZA200806070B
ZA200806070B ZA200806070A ZA200806070A ZA200806070B ZA 200806070 B ZA200806070 B ZA 200806070B ZA 200806070 A ZA200806070 A ZA 200806070A ZA 200806070 A ZA200806070 A ZA 200806070A ZA 200806070 B ZA200806070 B ZA 200806070B
Authority
ZA
South Africa
Prior art keywords
antagonist
treatment
combination
cognitive dysfunction
ache inhibitor
Prior art date
Application number
ZA200806070A
Other languages
English (en)
Inventor
Comery Thomas Anthony
Schechter Lee Erwin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200806070B publication Critical patent/ZA200806070B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200806070A 2006-01-13 2008-07-11 Combination of ache inhibitor and 5-HT6 antagonist for the treatment of cognitive dysfunction ZA200806070B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75884106P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
ZA200806070B true ZA200806070B (en) 2009-04-29

Family

ID=38109582

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806070A ZA200806070B (en) 2006-01-13 2008-07-11 Combination of ache inhibitor and 5-HT6 antagonist for the treatment of cognitive dysfunction

Country Status (20)

Country Link
US (1) US20070167431A1 (es)
EP (1) EP1971334A2 (es)
JP (1) JP2009523728A (es)
KR (1) KR20080096657A (es)
CN (1) CN101370499A (es)
AR (1) AR060019A1 (es)
AU (1) AU2007208516A1 (es)
BR (1) BRPI0706515A2 (es)
CA (1) CA2635920A1 (es)
CR (1) CR10139A (es)
EC (1) ECSP088619A (es)
GT (1) GT200800138A (es)
IL (1) IL192694A0 (es)
MX (1) MX2008009021A (es)
NO (1) NO20082894L (es)
PE (1) PE20071143A1 (es)
RU (1) RU2008126245A (es)
TW (1) TW200733976A (es)
WO (1) WO2007087151A2 (es)
ZA (1) ZA200806070B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
PT2040755E (pt) * 2006-06-23 2011-07-08 Esteve Labor Dr Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
WO2009074607A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RU2467749C1 (ru) * 2011-04-21 2012-11-27 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции уровня сахара крови и лечения пациентов с сахарным диабетом второго типа с когнитивными нарушениями
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
RU2719446C2 (ru) * 2014-11-03 2020-04-17 Айомет Фарма Лтд Фармацевтическое соединение
MX2017014192A (es) * 2015-05-07 2018-08-01 Axovant Sciences Gmbh Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
WO2017147601A1 (en) * 2016-02-25 2017-08-31 Axovant Sciences Gmbh Methods of improving balance, gait or both in patients with neurological disease
CN118806909A (zh) * 2016-04-26 2024-10-22 H.隆德贝克有限公司 乙酰胆碱酯酶抑制剂和艾达鲁吡啶用于减少帕金森氏病患者跌倒的用途
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
MX381768B (es) * 2016-05-18 2025-03-13 Suven Life Sciences Ltd Combinación de antagonistas puros del receptor 5-ht6 con inhibidores de la acetilcolinesterasa.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115102B1 (pt) * 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
KR20050085535A (ko) * 2002-12-11 2005-08-29 파마시아 앤드 업존 캄파니 엘엘씨 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법
BRPI0407253A (pt) * 2003-02-14 2006-01-31 Wyeth Corp Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
JP5146766B2 (ja) * 2005-08-15 2013-02-20 ワイス・エルエルシー ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体

Also Published As

Publication number Publication date
ECSP088619A (es) 2008-08-29
RU2008126245A (ru) 2010-02-20
BRPI0706515A2 (pt) 2011-03-29
WO2007087151A2 (en) 2007-08-02
AR060019A1 (es) 2008-05-21
CN101370499A (zh) 2009-02-18
CA2635920A1 (en) 2007-08-02
CR10139A (es) 2008-09-30
WO2007087151A3 (en) 2007-11-15
KR20080096657A (ko) 2008-10-31
US20070167431A1 (en) 2007-07-19
JP2009523728A (ja) 2009-06-25
AU2007208516A8 (en) 2008-08-07
IL192694A0 (en) 2009-02-11
AU2007208516A1 (en) 2007-08-02
PE20071143A1 (es) 2008-01-20
NO20082894L (no) 2008-09-30
MX2008009021A (es) 2008-09-24
GT200800138A (es) 2008-10-06
EP1971334A2 (en) 2008-09-24
TW200733976A (en) 2007-09-16

Similar Documents

Publication Publication Date Title
ZA200806070B (en) Combination of ache inhibitor and 5-HT6 antagonist for the treatment of cognitive dysfunction
ZA200804932B (en) Compounds for the inhibition of integrins and use thereof
IL205907A0 (en) 14-3-3 antagonists for the prevention and treatment of arthritis
IL197933A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
IL200766A0 (en) Compositions and methods for the prevention and treatment of autoimmune conditions
PT2439205E (pt) Compostos de carboxamida e seus usos como inibidores de calpaína
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EP2023874A4 (en) METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
IL190201A0 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
HUE041448T2 (hu) Kombinált telomerázgátló és gemcitabin rák kezelésére
IL197758A (en) New Benzophoran derivatives and preparations @ which include @@ the said @ for treatment or prevention of cognitive dysfunction @ impaired
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
EP2004216A4 (en) AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
IL205680A0 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
IL197966A0 (en) Use of modified cyclosporin
EP2049094A4 (en) MILNACIPRAN FOR THE TREATMENT OF COGNITIVE DYSFUNCTION ASSOCIATED WITH FIBROMYALGIA
IL194463A0 (en) Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
ZA200807615B (en) Renin inhibitors for the treatment of hypertension
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
HK1121401A (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
ZA200802668B (en) PDE inhibitors and combinations thereof for the treatment of urological disorders
GB0602857D0 (en) The treatment of sialorrhoea
PL1879609T3 (pl) Zastosowanie histonu w celach terapeutycznych
GB0507552D0 (en) Methods and compounds for the treatment of cognitive dysfunction